Medicus Pharma announced positive results from its Phase 2 SKNJCT-003 study using Doxorubicin Microneedle Array (D-MNA) to treat nodular basal cell carcinoma, the most common skin cancer. The 200µg dose cohort achieved a 55% complete histological response by Day 57, showing a clear dose-dependent improvement and potential to reduce the need for surgery. The treatment was well tolerated with no serious adverse effects, supporting further regulatory discussions with the FDA. These findings position the 200µg dose as a leading candidate for future registration and could change the current treatment approach for basal cell carcinoma.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
